Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab Vedotin in Advanced Small Bowel Adenocarcinoma
NCT07347314Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2025
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enfortumab vedotin in small bowel adenocarcinoma (SBA), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective Response Rate by central review up to 3 years. Started Nov 2025; status: recruiting.
02
Drugs
enfortumab vedotin
03
Conditions
small bowel adenocarcinoma (SBA)
Beyond the preview
Go deeper on NCT07347314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07347314.